CDNA vs TOKUY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CDNA · CareDx$78.56 ▲ 2.92%
TOKUY · Tokyu (ADR)$9.80 ▼ 8.33%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CDNA +370.4%
- TOKUY -15.2%
Head to head
| Metric | CDNA | TOKUY |
|---|---|---|
| Price | $78.56 | $9.80 |
| Change today | ▲ 2.92% | ▼ 8.33% |
| Market cap | $4.13B | $5.50B |
| Return, 3 months | +66.9% | -9.5% |
| Return, year to date | +317.0% | -12.9% |
| Return, 1 year | +402.9% | -15.2% |
| P/E (TTM) | 33.1 | 8.8 |
| P/B | 8.8 | 0.9 |
| P/E percentile vs own 5y | 100th | – |
| Dividend yield | – | 2.02% |
| Revenue growth (YoY, latest qtr) | +39.3% | – |
| Net profit growth (YoY) | +1,051.8% | – |
| Gross margin | 71.0% | – |
| Operating margin | 0.8% | – |
| Net margin | 25.9% | – |
| Return on equity | 33.0% | – |
| Analyst target vs. price | +3.5% | – |
| Analyst buy share | 75% | – |
| RSI (14) | 59 | 42 |
| 30-day volatility | 81.5% | 83.6% |
| Max drawdown, 1 year | -23.6% | -28.8% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TOKUY is the largest of the group by market value.
- CDNA has returned the most over the past year.
- TOKUY carries the lowest trailing P/E.
- CDNA has been the calmest stock over the last 30 days.